Abstract: The present disclosure provides a group of diagnostic biomarkers usable for diagnosis of colorectal cancer or colorectal adenoma. A method for detecting colorectal cancer or colorectal adenoma using the group of diagnostic biomarkers is also provided. For example, the method provided by the present disclosure is a non-invasive approach that may utilize serum samples for detecting colorectal cancer. Moreover, the method for detecting colorectal cancer may detect colorectal cancer of different stages (e.g., pre-cancer stage, early stage, middle stage, late stage).

Abstract: The present disclosure provides a group of diagnostic biomarkers usable for diagnosis of colorectal cancer or colorectal adenoma. A method for detecting colorectal cancer or colorectal adenoma using the group of diagnostic biomarkers is also provided. For example, the method provided by the present disclosure is a non-invasive approach that may utilize serum samples for detecting colorectal cancer. Moreover, the method for detecting colorectal cancer may detect colorectal cancer of different stages (e.g., pre-cancer stage, early stage, middle stage, late stage).

Abstract: The invention relates to the identification and use of gene expression profiles with clinical relevance to the treatment of cellular proliferative disorders, especially those mediated by aberrant Notch signaling using a Notch signaling inhibitor. In particular, the invention provides the identities of genes, whose individual or cumulative expression patterns may be useful in various assays. The gene expression profiles, whether embodied in nucleic acid expression, protein expression, or other expression formats, may be used to select subjects afflicted with a Notch mediated cancer who will likely respond to treatment with a gamma-secretase inhibitor or another Notch inhibiting agent. The same markers may be used in the classification of patients being treated with other Notch inhibitors. The methods may further comprise providing diagnostic, prognostic, or predictive information based on the classifying step. The methods may further comprise selecting a treatment based on the classifying step.

Abstract: The present invention provides compositions and methods for predicting the hypoxia response in tumor cells, methods for predicting the likelihood of cancer metastasis, and methods for inhibiting tumor cell proliferation using a microRNA comprising miR-210.

Abstract: The invention provides methods for characterizing the condition or status of a tissue or organ in a multicellular organism, e.g., an animal, by combining a plurality of clinical measures are combined into a composite clinical score (CCS) and using such a CCS to represent the condition or status of the tissue or organ. The invention provides methods for predicting the condition or status of a tissue or organ in a multicellular organism, e.g., an animal, based on measurements of a set of cellular constituent markers, e.g., measured expression levels of a set of marker genes. The invention also provides methods for selecting the set of marker genes whose expression levels can be used in determining the CCS.

Abstract: An iterative process to associate patterns embedded in the profiles of biological signals, including gene expression profile, protein profiles, with certain cellular status, functional stages and response to permutations. The biological signals, including gene expression profile, are converted into frequency domains using wavelet transform or other frequency transforms at different scales after rearranging the order of genes. These biological signals in the frequency domain are associated with certain cellular status, functional stages and response to permutation with neural network learning. An error rate is used to determine the optimal combination of wavelet function, scale and gene order. The information enriched gene group can be extracted from the frequency domain as well.